Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

Leukemia

Volumn 26, Issue 12, 2012, Pages 2462-2468

  Baron, F ^a   Labopin, M ^b   Niederwieser, D ^c   Vigouroux, S ^d   Cornelissen, J J ^e   Malm, C ^f   Vindelov, L L ^g   Blaise, D ^h   Janssen, J J W M ⁱ   Petersen, E ^j   Socie G ^k   Nagler, A ^l   Rocha, V ^m,n   Mohty, M ^b,n,o,p  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b HÔPITAL SAINT ANTOINE   (France)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g Rigshospitalet   (Denmark)

^h ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^k SAINT LOUIS HOSPITAL   (France)

^l TEL AVIV UNIVERSITY   (Israel)

^m EUROCORD   (France)

ⁿ EBMT ALWP   (France)

^o UNIVERSITÉ DE NANTES   (France)

^p Team 12   (France)

more..

Author keywords

AML; chronic; graft versus leukemia effects; GVHD; reduced intensity conditioning

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IN VIVO STUDY; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; T CELL DEPLETION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84871228768     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.135     Document Type: Article

References (34)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
2. Gupta V, Tallman MS, Weisdorf DJ. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia: myths, controversies, and unknowns. Blood 2011; 117: 2307-2318.
3. Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720-1728.
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
5. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001; 411: 385-389.
6. Kolb HJ, Schmidt C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767-776.
7. Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92: 533-541.
8. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb H-J et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312.
9. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
10. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Non-myeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
11. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26: 577-584.
12. Blaise DP, Michel BJ, Faucher C, Mohty M, Bay JO, Bardoux VJ et al. Reduced intensity conditioning prior to allogeneic stem cell transplantation for patients with acute myeloblastic leukemia as a first-line treatment. Cancer 2005; 104: 1931-1938.
13. de Lima M, Giralt S. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome. Semin Hematol 2006; 43: 107-117.
14. van Besien K, Artz A, Smith S, Cao D, Rich S, Godley L et al. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005; 23: 5728-5738.
15. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387-9393.
16. Lazarus HM, Rowe JM. Reduced-intensity conditioning for acute myeloid leukemia: is this strategy correct. Leukemia 2006; 20: 1673-1682.
17. Estey E, de Lima M, Tibes R, Pierce S, Kantarjian H, Champlin R et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hemato-poietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109: 1395-1400.
18. McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28: 1878-1887.
19. Shimoni A, Hardan I, Shem-Tov N, Yeshurun M, Yerushalmi R, Avigdor A et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006; 20: 322-328.
20. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993-2003.
21. Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I et al. Allogeneic hemato-poietic stem cell transplantation for the treatment of high-risk acute myelo-genous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 2007; 13: 454-462.
22. Craddock C, Nagra S, Peniket A, Brookes C, Buckley L, Nikolousis E et al. Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2010; 95: 989-995.
23. van Besien K, Kunavakkam R, Rondon G, de Lima M, Artz A, Oran B et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant 2009; 15: 610-617.
24. Weisdorf DJ, Zhang MJ, Arora M, Rizzo JD, Horowitz MM, Eapen M. Graft-versus-host disease (GVHD) induced graft-versus-leukemia (GVL) effect: more impact on later relapse and disease-free survival following reduced intensity conditioning. ASH Ann Meeting Abstracts 2011; 118: 1014.
25. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
27. Giebel S, Labopin M, Mohty M, Blaise D, Craddock C, Nagler A et al. The impact of center experience on results of reduced intensity\allogeneic hematopoietic stem cell transplantation. A survey from the Acute Leukemia Working Party (ALWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2010; 11: 1445-1446.
28. Baron F, Storb R. Hematopoietic cell transplantation after reduced-intensity conditioning for older adults with acute myeloid leukemia in complete remission. Curr Opin Hematol 2007; 14: 145-151.
29. Storer BE. Statistical considerations in studies of late effects in HCT. Biol Blood Marrow Transplant 2009; 15(1 Suppl): 25-28.
30. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
31. Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E et al. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the Acute Leukemia Working Party of EBMT. Bone Marrow Transplant 2012; e-pub ahead of print 16 April 2012; doi:10.1038/bmt.2012.55.
32. Luger SM, Ringden O, Zhang MJ, Perez WS, Bishop MR, Bornhauser M et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 2012; 47: 203-211.
33. Pidala J, Kim J, Jim H, Fernandez HF, Tomblyn M, Kharfan-Dabaja MA et al. Sirolimus/tacrolimus facilitates preferential recovery of regulatory T cells (Treg) after allogeneic hematopoietic cell transplantation (HCT), and is more effective than methotrexate/tacrolimus in preventing grade II-IV acute graft vs host disease (GVHD) and moderate to severe chronic GVHD. Blood 2011; Annual ASH meeting supplement: 323a.
34. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea III EP et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365: 2055-2066.